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ESMO Minimum Clinical Recommendations for diagnosis,
treatment and follow-up of chronic lymphocytic leukemia
Incidence
. B-chronic lymphocytic leukemia (B-CLL) has an incidence
of 3/100 000 per year in the western hemisphere. The inci-
dence is increasing up to almost 50/100 000 per year after
the age of 70 years. The incidence was reported to increase
in younger patients, with about one-third of B-CLL patients
younger than 55 years old. However, this trend does not
seem to have changed the overall incidence of B-CLL so
far. B-CLL represents the most frequent non-Hodgkin’s
lymphoma (11%) and leukemia of adults (25%).
Diagnosis
. The diagnosis of B-CLL is established by the following
criteria:
Sustained increase of peripheral blood lymphocytes
>_5 109 cells/l not explained by other clinical
disorders.
Predominance of small, morphologically mature
lymphocytes in the blood smear.
Immunophenotyping: The composite immunopheno-
type CD5 + , CD23 + , CD20 dim + , sIg dim + ,
FMC7 allows one to distinguish most cases of
B-CLL from other CD5 + B-cell lymphoma. The
Matutes score may be helpful in this regard.
Lymph node biopsy: Histological confirmation is
recommended whenever an enlarged, accessible, per-
ipheral lymph node allows the procedure without
additional risk.
The following additional examinations are rec-
ommended for the initial evaluation [V, D]:
Physical examination including a careful palpation
of all lymph node areas.
LDH, b2-microglobulin, bilirubin, serum–protein
electrophoresis, Coombs test.
Chest X-ray, abdominal ultrasound or computer
tomography.
. FISH is becoming increasingly used for risk stratification
and for choosing the treatment of choice in selected younger
high risk patients.
. For prognostic and therapeutic reasons, every effort should be
made for adequate differential diagnosis against mantle cell
lymphoma using morphology, immunophenotyping and fluo-
rescence in situ hybridization and/or molecular biology for
detection of (t11;14) translocation and staining for cyclin D1.
Staging and prognosis
. The median survival at diagnosis varies between 2 and >10
years according to the initial stage of the disease. Two
clinical staging systems are used. In Europe, the Binet sta-
ging system is generally more accepted. It separates three
groups of different prognosis (Table 1).
Treatment of early disease
. (Binet stage A and B without symptoms; Rai 0, I and II
without symptoms.)
. The standard treatment of patients with early disease is a
watch and wait strategy with controls of blood cell counts
and clinical examinations every three months [I, A]. Patients
with rapid disease progression (lymphocyte doubling time
<12 months) should be treated as below.
Treatment of advanced disease
. (Binet stage A and B with symptoms, Binet stage C; Rai II
with symptoms, Rai III–IV.)
. B-symptoms, cytopenias not caused by autoimmune
phenomena and symptoms or complications from lymphade-
nopathy, splenomegaly or hepatomegaly are indications for
chemotherapy [I, A].
. Options are purine analogues (fludarabine, cladribine) or
chlorambucil. Randomized trials have not demonstrated a
survival benefit for either option so far [I, A].
. In younger patients (<_65 years, physically active, no
major health problems) purine analogues may be rec-
ommended as initial treatment, because they achieve a
higher rate of complete remissions and a longer pro-
gression- and treatment-free survival than chlorambucil.
The risks and benefits of fludarabine are better documen-
ted than those of other purine analogues. Combinations
of purine analogues with other drugs, in particular cyclo-
phosphamide appear to result in a higher complete remis-
sion rate than single agent therapy, but with a higher
toxicity.
. In older patients (>65 years, with high comorbidity) chlor-
ambucil can be given as first line therapy, because it is less
myelotoxic and immunosuppressive than purine analogues
thus resulting in fewer infections.
Second-line chemotherapy
. The first line treatment may be repeated, if the relapse or pro-
gression occurs >6 months after the initial therapy [V, D].
. If the relapse occurs within 6 months or if the disease does
not respond to the first line therapy, the following options
are recommended [V, D]:
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. Fludarabine after chlorambucil.
. Fludarabine combinations (with cyclophosphamide and / or
mitoxantrone (FCM) in fludarabine refractory patients.
. Monoclonal antibody (alemtuzumab) in chemotherapy
refractory patients.
. High dose therapy followed by autologous or allogeneic
progenitor cell transplantation remains investigational.
Response evaluation
. Response evaluation includes a blood cell count and a mar-
row biopsy (only in patients with complete hematologic
remission), as well as a chest X-ray and an abdominal ultra-
sound or computer tomography [V, D].
Follow-up
. Follow up of asymptomatic patients should include a blood
cell count every 3 months, as well as a regular examinations
of lymph nodes, liver and spleen. Special attention should
be given to the number of atypical lymphocytes in particular
to prolymphocytes [V, D].
Note
Levels of Evidence [I–V] and Grades of Recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts
and the ESMO faculty.
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Table 1. Prognostic stages of CLL
Frequency (%) Median survival
Binet stage:
A 63 >10 years
B 30 5 years
C 7 1.53 years
Rai stage:
0 Low 30 >10 years
I
Intermediate 60 7 years
II
III
High 10 1.5 years
IV
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